SCHEMBL12857773

SCHEMBL12857773

[C-]#[N+]c1ccc(C(=O)O)nc1SCc1ccc(C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ TP53 P04637 1/20 0.48
▸ MAPT P10636 4/20 0.39
▸ CYP2C9 P11712 2/20 0.39
▸ GAA P10253 1/20 0.39
▸ PPARG P37231 1/20 0.39
▸ POLB P06746 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ PTGDR2 Q9Y5Y4 1/20 0.38
▸ ALDH1A1 P00352 4/20 0.38
▸ HPGD P15428 2/20 0.38
▸ LMNA P02545 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ RAB9A P51151 1/20 0.37
▸ MAPK1 P28482 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12857837 0.88 PPARG (0.47) SMN1; SMN2TP53CYP2C9PPARGALDH1A1
SCHEMBL12857772 0.87 HTT (0.43) SMN1; SMN2MAPTCYP2C9PPARGPOLB
SCHEMBL12858010 0.86 FFAR1 (0.46) SMN1; SMN2TP53MAPTCYP2C9GAA
SCHEMBL12858080 0.85 PTGDR2 (0.43) SMN1; SMN2TP53MAPTPPARGMEN1
SCHEMBL12857316 0.81 RAB9A (0.42) SMN1; SMN2TP53MAPTCYP2C9GAA
SCHEMBL1142831 0.77 MAPT (0.61) SMN1; SMN2TP53MAPTGAAPPARG
SCHEMBL12857722 0.76 NTRK1 (0.42) SMN1; SMN2MAPTCYP2C9GAAMEN1
SCHEMBL12857771 0.75 KMT2A (0.51) MAPTGAAPOLBMEN1KMT2A
SCHEMBL12857859 0.75 ALDH1A1 (0.47) SMN1; SMN2MAPTGAAPOLBMEN1
SCHEMBL12857758 0.74 KDM4E (0.36) MAPTMEN1KMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9340505-B2 Type III secretion inhibitors, analogs and uses thereof UNIVERSITY OF MASSACHUSETTS (US) 2016-05-17 — — US disclosed
US-20140323483-A1 TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF UNIVERSITY OF MASSACHUSETTS (US) 2014-10-30 — — US disclosed
US-20110034463-A1 TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-02-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034463-A1 TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF GBA3, CLPP, PEX3 SMN1; SMN2 4655/4885TP53 3850/4885MAPT 3404/4885
US-20140323483-A1 TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF GBA3, CLPP, PEX3 SMN1; SMN2 4655/4885TP53 3850/4885MAPT 3404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback